TNYA实时信号 | 通过Getagraph.com最大化利润

出售 112235 min ago

@ $5.35

发出时间: 14 Feb 2024 @ 22:30

回报率: -12.52%

上一信号: Feb 13 - 00:24

上一信号: 购买

回报率: -6.14 %

Live Chart Being Loaded With Signals

Commentary (2 May 2024 @ 04:00):

Stats
今日成交量	152 978
平均成交量	526 504
市值	367.46M
EPS	$-0.390 ( 2024-03-20 )
下一个收益日期	( $-0.430 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.79
ATR14	$0.0120 (0.26%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-05	Hoey Timothy	Sell	3 300	Common Stock
2024-02-23	Hoey Timothy	Buy	12 500	Common Stock
2024-02-23	Hoey Timothy	Buy	75 000	Stock Option (Right to buy)
2024-02-23	Tingley Whittemore	Buy	215 000	Stock Option (Right to buy)
2024-02-23	Tingley Whittemore	Buy	35 000	Common Stock

INSIDER POWER
99.35
Last 96 transactions
Buy: 62 840 535 \| Sell: 9 767 330

音量相关性

長: 0.35 (neutral)

短: -0.74 (moderate negative)

Signal:(31.141) Neutral

Tenaya Therapeutics, Inc. 相关性

10 最正相关
MDRR	0.829
RESN	0.81

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Tenaya Therapeutics, Inc. 相关性 - 货币/商品

0.61
( weak )

0.51
( weak )

0.00
( neutral )

0.77
( moderate )

0.02
( neutral )

-0.88
( strong negative )

Tenaya Therapeutics, Inc. 财务报表

Annual	2023
营收:	$0
毛利润:	$-8.69M (0.00 %)
EPS:	$-1.680

FY	2023
营收:	$0
毛利润:	$-8.69M (0.00 %)
EPS:	$-1.680

FY	2022
营收:	$0
毛利润:	$-8.71M (0.00 %)
EPS:	$-2.76

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.00269

Financial Reports:

No articles found.

Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.